

# Supporting Information

Menotti et al. 10.1073/pnas.0812268106

## SI Materials and Methods


**Engineering of R-LM249.** BAC LM249 was constructed by 2-step replacement in *Escherichia coli*, as described (1–4). The pS249 shuttle vector carries the coding sequence for a chimeric glycoprotein gD engineered with a single chain antibody (scFv) anti HER-2 flanked by serine-glycine linkers (upstream 8 aa residues: HSSGGGSG; downstream 12 aa residues: SSGGGSGSGGSG) in place of gD amino acid residues 61 to 218. Mutagenesis and cloning was performed on pLM5, a plasmid containing WT-gD plus  $\approx$ 500 bp upstream and downstream flanking sequences (4, 5). First, 2 NdeI sites were inserted at the coding sequence for gD amino acid residues 61–62 and 218–219 of mature gD with mutagenic primers gD\_61/62\_NdeLf (5'-ACG GTT TAC TAC GCC CAT ATG GAG CGC GCC TGC C-3') and gD\_218/219\_NdeLf (5'-GAC GGT GGA CAG CAT CCA TAT GCT GCC CCG CTT C-3'). Next, an oligo encoding a 9 aa serine-glycine linker was inserted in place of the sequence encoding amino acid 61–218 of gD by annealing and ligating into the NdeI cut vector the 2 phosphorylated oligos P-SG9Bam7/Nde.f (5'-TAG TAG TGG CGG TGG CTC TGG ATC CGG-3') and P-SG9Bam7/Nde.r (5'-TAC CGG ATC CAG AGC CAC CGC CAC TAC-3'), containing a silent BamHI site. The scFv to HER-2 was amplified from pS2019a (6) with primers scFv\_Bam.f (5'-GGC TTA TGG ATC CGA TAT CCA GAT GAC CCA GTC CCC-3') and scFv\_SG\_x37\_BamH.r (5'-CGG AGG ATC CAC CGG AAC CAG AGC CAC CGC CAC TCG AGG-3') and inserted into the BamHI site of the serine-glycine linker. Last, the cassette containing the engineered gD, plus gD

genomic upstream and downstream flanking sequences was subcloned to pST76KSR shuttle vector to obtain pS249 for homologous recombination in *E. coli*. The receiving genome gDminus-EGFP-HSV-BAC, carrying EGFP as reporter gene, was described in ref. 4.


The recombinant virus, designated R-LM249, was reconstituted as described in ref. 4. Briefly, the BAC-DNA was transfected into WT-gD-expressing and complementing R6 cells (7); next, a single passage in BHK cells was performed to remove any virus pseudotyped with WT-gD; finally the virus was serially passaged in SK-OV-3 cells. Infection was monitored by observation of the cytopathic effect and EGFP. Viral stocks were prepared from lysates of infected SK-OV-3 cells collected at low speed centrifugation. Extracellular virions were harvested from infected cell supernatants by ultracentrifugation ( $215,000 \times g$  for 75 min) on a sucrose cushion (25% in PBS). The titer of viral stocks and extracellular virion preparations was determined in SK-OV-3 cells monolayers, overlaid with 1% SeaPlaque Agarose in RPMI+Glutamax-I, supplemented with 6% FBS.

**HER-2 Expression.** HER-2 expression in J, J-HER-2, SJ-Rh4, MCF-7, MDA-MB-453, SK-BR-3, and SK-OV-3 cell lines was evaluated by indirect immunofluorescence with monoclonal antibody MGR-3 (kindly given by S. Pupa, National Cancer Institute, Milan) (8), followed by Alexa-Fluor 488-conjugated anti-mouse IgG (Invitrogen). After final washings, cells were resuspended in PBS containing 1  $\mu$ g/mL of ethidium bromide to gate out dead cells, and analyzed by FACScan flow cytometry (Becton Dickinson).

1. Borst EM, Hahn G, Koszinowski UH, Messerle M (1999) Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in *Escherichia coli*: A new approach for construction of HCMV mutants. *J Virol* 73:8320–8329.
2. Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH (1997) Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. *Proc Natl Acad Sci USA* 94:14759–14763.
3. O'Connor M, Peifer M, Bender W (1989) Construction of large DNA segments in *Escherichia coli*. *Science* 244:1307–1312.
4. Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G (2008) Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. *J Virol* 20:10153–10161.
5. Menotti L, Cerretani A, Campadelli-Fiume G (2006) A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. *J Virol* 80:5531–5539.
6. Sidhu SS, et al. (2004) Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. *J Mol Biol* 338:299–310.
7. Zhou G, Galvan V, Campadelli-Fiume G, Roizman B (2000) Glycoprotein D or J delivered *in trans* blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins. *J Virol* 74:11782–11791.
8. Ricci C, et al. (2002) HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells. *J Immunother* 25:314–323.



**Fig. S1.** Schematic representation of the genome of WT HSV-1 and of recombinants relevant to this study used for the generation of R-LM249. (a) WT HSV-1 genome linear map. (b) Genomic organization of gD-minus-EGFP-HSV-BAC, the recipient genome for BAC mutagenesis. BAC sequences are located between UL3 and UL4 genes, and contain EGFP reporter gene under control of viral immediate-early  $\alpha 27$  promoter; gD is deleted ( $\Delta$ ). (c) Enlarged view of the gD region. Genomic sequences upstream and downstream of gD are represented by boxes with different grayscale filling, respectively; gD ORF is replaced by a FRT site. (d) Schematic representation of pS249 shuttle vector. The cassette contains, in order: gD upstream genomic sequence ( $\approx 500$  bp), the coding sequences for gD aa residues 1–60, the 8-aa serine-glycine linker, the scFv to HER-2, the 12-aa serine-glycine linker, gD aa residues 219–369, followed by gD downstream genomic region ( $\approx 500$  bp). The elements are depicted as boxes with different grayscale filling. Numbers indicate the amino acid residues of gD maintained at the boundary of the deletion. (e) Two sequential recombination events in *E. coli* (arrow, and nos. 1 and 2) between homologous sequences present in the recipient HSV genome and in the shuttle vector yield the final recombinant R-LM249. (f) R-LM249 genome organization.  $\Delta$ , deletion; FRT, FLP recombinase recognition target; gD, glycoprotein D; IR, inverted repeats; scFv, single-chain antibody; UL, unique long genomic region.



**Fig. S2.** Membrane expression of HER-2, determined by flow cytometry after indirect immunofluorescence with anti-HER-2 monoclonal antibody (red profiles) or secondary antibody alone (empty profiles). HER-2 median fluorescence intensities were: J, 4; J-HER-2, 407; SJ-Rh4, 4; MCF-7, 72; MDA-MB-453, 340; SK-BR-3, 1241; and SK-OV-3, 1655.